Deprescribing Guidelines: Managing Polypharmacy Safely

Added:

The Risks of Under-Prescribing and Clinical Rebound

While deprescribing aims to reduce polypharmacy, critics and clinical researchers highlight the risks of under-prescribing, therapeutic nihilism, and adverse withdrawal events. Aggressively stopping medications can lead to the undertreatment of chronic conditions, causing disease relapse or acute exacerbations, such as rebound hypertension or cardiac events. Furthermore, the psychological impact on patients—including anxiety, confusion, and fear of illness return—is often underestimated. Opponents of over-zealous deprescribing also point to a critical evidence gap: while guidelines are abundant, robust clinical trial data demonstrating that systematic deprescribing consistently improves hard clinical outcomes like mortality or hospitalization rates remain limited. Consequently, some experts advocate for 'prescribing optimization' rather than a default reductionist strategy, emphasizing that polypharmacy is often clinically appropriate and necessary to manage complex, multi-morbid patients safely.

Basic principles of pharmacology, pharmacokinetics, and pharmacodynamics, particularly how drug clearance and metabolism change in older adults.
The clinical definition of polypharmacy, including its common causes, risks, and its association with adverse drug events (ADEs).
Familiarity with common drug classes frequently prescribed to patients with chronic conditions (e.g., proton pump inhibitors, benzodiazepines, antihypertensives).
The concept of clinical risk-benefit analysis, specifically how a medication's therapeutic value may change over a patient's lifespan.
In-depth application of validated clinical screening tools for inappropriate prescribing, such as the Beers Criteria and STOPP/START criteria.
Strategies for effective patient communication and shared decision-making to address patient anxiety or resistance regarding medication tapering and discontinuation.
Protocols for monitoring patients post-deprescribing, including recognizing and managing drug withdrawal syndromes or the re-emergence of symptoms.
Implementation of interprofessional collaborative care models (such as pharmacist-led Medication Therapy Management) to audit and optimize drug regimens in clinical settings.
39.8K views155likes8:14@deprescribingOriginal Release: 2017-05-17

Evidence-based deprescribing guidelines are systematically developed tools that help healthcare professionals safely reduce or stop medications that may no longer be needed or are causing more harm than benefit, particularly in older adults who are at higher risk for medication-related harm due to changing health conditions, increased sensitivity to side effects, and reduced drug elimination capacity; these guidelines use the GRADE approach to assess evidence quality and provide actionable algorithms for dose reduction or discontinuation while maintaining patient safety and quality of life.